Moderate quality evidence shows reduction in frequency of hot flashes with paroxetine
TUESDAY, April 19, 2016 (HealthDay News) — For perimenopausal and postmenopausal women, paroxetine reduces vasomotor symptoms, according to a review and meta-analysis published online April 7 in BJOG: An International Journal of Obstetrics and Gynaecology.
Dang Wei, from Lanzhou University in China, and colleagues conducted a systematic review to confirm the effect and safety of paroxetine for vasomotor symptoms. Data were included from five articles with six randomized controlled trials (1,571 participants who experienced moderate-to-severe vasomotor symptoms) that compared paroxetine with placebo or no treatment.
The researchers found that at week four and week 12, paroxetine reduced the frequency of hot flashes by 8.86 and 7.36 per week, respectively (both P < 0.00001). The evidence on the effect of paroxetine was of moderate quality. The most consistently reported adverse effects were nausea, dizziness, headache, fatigue, and constipation; nausea and dizziness were 2.45- and 2.44-times higher than placebo, respectively.
“Paroxetine is effective for reducing vasomotor symptoms in menopausal women, and this finding is supported by moderate quality evidence,” the authors write. “However, nausea and dizziness are more common in women taking paroxetine than placebo.”
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease 
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer 
Type 2 Diabetes Linked to Worse Menopausal Symptoms 
Premature Menopause Linked to Increased Risk for Hypertension 
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians 
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions 
Phthalates From Personal Care Products Tied to Higher BP in Pregnancy 
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death 
